These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27656950)

  • 1. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
    Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
    J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    El-Karaksy HM; Mogahed EA; El-Raziky MS; Saleh D; Besheer M; Mubarak S
    J Interferon Cytokine Res; 2016 Jan; 36(1):1-8. PubMed ID: 26406390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.
    Wang KL; Xing HQ; Zhao H; Liu JW; Gao DL; Zhang XH; Yao HY; Yan L; Zhao J
    World J Gastroenterol; 2014 Apr; 20(14):4071-5. PubMed ID: 24744598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB; Atabay A; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.
    Ucmak H; Kokoglu OF; Hosoglu S; Dogan E; Sayarlioglu H; Kuzhan N; Isik IO
    Ren Fail; 2008; 30(2):227-32. PubMed ID: 18300126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
    Ahn SB; Jun DW; Kim SG; Lee SH; Shin HP; Choe WH; Kim JK; Jung KS; Kim DY; Shim JJ; Park SY; Seo YS; Kim W; Chung JI
    Eur J Intern Med; 2015 May; 26(4):292-6. PubMed ID: 25877760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
    J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
    J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Ayaz C; Celen MK; Yuce UN; Geyik MF
    World J Gastroenterol; 2008 Jan; 14(2):255-9. PubMed ID: 18186564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.